ABCR评分系统对经肝动脉化疗栓塞术治疗肝细胞癌预后的评估价值
摘要:目的评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略。方法选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者。为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗 (至少2次,且不联合全身系统治疗) 的229例患者为A组,并分为A1组 (ABCR评分≤0,n=92) 、A2组 (ABCR评分:1～3分,n=78) 和A3组 (ABCR评分≥4,n=59) ;为研究ABCR评分为1-3分患者首次TACE治疗后接受不同治疗方案的生存期,选取首次行TACE治疗的ABCR评分为1～3...
Saved in:
| Published in | Linchuang gandanbing zazhi Vol. 36; no. 9; pp. 1980 - 1984 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | Chinese |
| Published |
Changchun
Journal of Clinical Hepatology
01.09.2020
苏州大学附属第一医院介入科,江苏苏州215000 |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1001-5256 2097-3497 |
| DOI | 10.3969/j.issn.1001-5256.2020.09.014 |
Cover
| Abstract | 摘要:目的评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略。方法选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者。为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗 (至少2次,且不联合全身系统治疗) 的229例患者为A组,并分为A1组 (ABCR评分≤0,n=92) 、A2组 (ABCR评分:1～3分,n=78) 和A3组 (ABCR评分≥4,n=59) ;为研究ABCR评分为1-3分患者首次TACE治疗后接受不同治疗方案的生存期,选取首次行TACE治疗的ABCR评分为1～3分的118例患者为B组,分为B1组 (首次TACE后继续TACE,n=78) 、B2组 (TACE联合索拉非尼,n=21) 和B3组 (索拉非尼单药治疗,n=19) 。分析以上各组患者的生存情况。计数资料组间比较采用Fisher精确检验,Kaplan-Meier法绘制生存曲线,log-rank检验比较各组生存期。结果 A1组中位生存期32.0个月 (95%CI:27.7～36.3) ; A2组中位生存期10.3个月 (95%CI:8.4... |
|---|---|
| AbstractList | 摘要:目的评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略。方法选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者。为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗 (至少2次,且不联合全身系统治疗) 的229例患者为A组,并分为A1组 (ABCR评分≤0,n=92) 、A2组 (ABCR评分:1～3分,n=78) 和A3组 (ABCR评分≥4,n=59) ;为研究ABCR评分为1-3分患者首次TACE治疗后接受不同治疗方案的生存期,选取首次行TACE治疗的ABCR评分为1～3分的118例患者为B组,分为B1组 (首次TACE后继续TACE,n=78) 、B2组 (TACE联合索拉非尼,n=21) 和B3组 (索拉非尼单药治疗,n=19) 。分析以上各组患者的生存情况。计数资料组间比较采用Fisher精确检验,Kaplan-Meier法绘制生存曲线,log-rank检验比较各组生存期。结果 A1组中位生存期32.0个月 (95%CI:27.7～36.3) ; A2组中位生存期10.3个月 (95%CI:8.4... R735.7; 目的 评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略.方法 选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者.为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗(至少2次,且不联合全身系统治疗)的229例患者为A组,并分为A1组(ABCR评分≤0,n=92)、A2组(ABCR评分:1～3分,n=78)和A3组(ABCR评分≥4,n=59);为研究ABCR评分为1-3分患者首次TACE治疗后接受不同治疗方案的生存期,选取首次行TACE治疗的ABCR评分为1～3分的118例患者为B组,分为B1组(首次TACE后继续TACE,n=78)、B2组(TACE联合索拉非尼,n=21)和B3组(索拉非尼单药治疗,n=19).分析以上各组患者的生存情况.计数资料组间比较采用Fisher精确检验,Kaplan-Meier法绘制生存曲线,log-rank检验比较各组生存期.结果 A1组中位生存期32.0个月(95％CI:27.7～36.3);A2组中位生存期10.3个月(95％CI:8.4～12.2);A3组中位生存期4.6个月(95％CI:3.7～5.5).A1组生存期优于A2组(χ2=106.99,P<0.01),A2组生存期优于A3组(χ2=49.66,P<0.01).B1组中位生存期10.3个月(95％CI:8.4～12.2),B2组中位生存期14.8个月(95％CI:7.8～21.8),B3组中位生存期6.0个月(95％CI:4.6～7.4),B2组生存期优于B1组(χ2=6.80,P<0.01)和B3组(χ2=29.89,P<0.01).结论 ABCR评分对肝细胞癌患者的治疗有一定指导意义,ABCR评分≤0,可考虑继续TACE治疗;评分≥4,TACE治疗可能无法使患者获益;评分为1～3,TACE联合索拉非尼可能使患者生存期获益最大. |
| Author | 李智 印于 张申 黄鹏 王万胜 朱晓黎 杨俊 倪才方 |
| AuthorAffiliation | 苏州大学附属第一医院介入科,江苏苏州215000 |
| AuthorAffiliation_xml | – name: 苏州大学附属第一医院介入科,江苏苏州215000 |
| Author_FL | NI Caifang HUANG Peng ZHANG Shen WANG Wansheng YIN Yu ZHU Xiaoli YANG Jun LI Zhi |
| Author_FL_xml | – sequence: 1 fullname: YANG Jun – sequence: 2 fullname: YIN Yu – sequence: 3 fullname: NI Caifang – sequence: 4 fullname: ZHU Xiaoli – sequence: 5 fullname: LI Zhi – sequence: 6 fullname: ZHANG Shen – sequence: 7 fullname: HUANG Peng – sequence: 8 fullname: WANG Wansheng |
| Author_xml | – sequence: 1 fullname: 杨俊 – sequence: 2 fullname: 印于 – sequence: 3 fullname: 倪才方 – sequence: 4 fullname: 朱晓黎 – sequence: 5 fullname: 李智 – sequence: 6 fullname: 张申 – sequence: 7 fullname: 黄鹏 – sequence: 8 fullname: 王万胜 |
| BookMark | eNpFkE1LAlEYhS9hkJm_ohZtZnrvx9yZuzTpC4Qgci3zcRVFRnOSwFXUIBVSQWAUZR-rdkYtIsaf4zjTv2jCqNXhPefhvHDmUcptuBKhJQwqFVys1NSq57kqBsCKRjSuEiCgglABsxmUJiB0hTKhp1D6j5lDWc-rWqBhygXTeBoVc6v5nXjohyfd6D2Igodw-BkFF_HRfXj2EvunYa8f9a8nj1fh02ByN5y8BcmZpFHQjY8H0U3v69kPL8-jWz8pGY9ex8FHeDhaQLNls-7J7K9mUHF9bTe_qRS2N7byuYLSxBQzRTNt2wTbENzAQnKrLJmwOOfEcQwQkjpEMAc40w0suaELTqjUdWJYIHliaDSDlqe9B6ZbNt1KqdZot9zkY6luVxyr0_nZBESySIIuTtFmq7HXlt7-P0sJA0wFBaDf5j2AdA |
| ClassificationCodes | R735.7 |
| ContentType | Journal Article |
| Copyright | 2020. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: 2020. This work is published under https://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3969/j.issn.1001-5256.2020.09.014 |
| DatabaseName | ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials PROQUEST ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitle | Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) |
| DatabaseTitleList | Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitle_FL | Value of ABCR scoring system in assessing the prognosis of hepatocellular carcinoma after transcatheter arterial che-moembolization |
| EISSN | 2097-3497 |
| EndPage | 1984 |
| ExternalDocumentID | lcgdbzz202009014 |
| GrantInformation_xml | – fundername: 苏州市科技计划项目 funderid: (SYS2019036) |
| GroupedDBID | -05 3V. 5XA 5XF 7X7 7XB 88E 8FI 8FJ 8FK 92F 92I ABDBF ABJNI ABUWG ACGFS ACUHS AFKRA ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR CCEZO CCPQU CIEJG CW9 DWQXO EAD EAP EOJEC ESX FYUFA K9. M1P OBODZ OK1 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI RNS TCJ TGQ U1G U5O 2B. 4A8 93N IPNFZ PSX RIG |
| ID | FETCH-LOGICAL-p1314-5acca0c896819e6bfe49b6662dd809e3d294d064781e6879623e7728b0e6e6853 |
| IEDL.DBID | BENPR |
| ISSN | 1001-5256 |
| IngestDate | Thu May 29 04:06:09 EDT 2025 Sat Aug 23 13:08:29 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | 化学栓塞,治疗性 索拉非尼 癌,肝细胞 ABCR评分 |
| Language | Chinese |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-p1314-5acca0c896819e6bfe49b6662dd809e3d294d064781e6879623e7728b0e6e6853 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 |
| OpenAccessLink | https://www.proquest.com/docview/3240139300?pq-origsite=%requestingapplication%&accountid=15518 |
| PQID | 3240139300 |
| PQPubID | 7350069 |
| PageCount | 5 |
| ParticipantIDs | wanfang_journals_lcgdbzz202009014 proquest_journals_3240139300 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-09-01 |
| PublicationDateYYYYMMDD | 2020-09-01 |
| PublicationDate_xml | – month: 09 year: 2020 text: 2020-09-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Changchun |
| PublicationPlace_xml | – name: Changchun |
| PublicationTitle | Linchuang gandanbing zazhi |
| PublicationTitle_FL | Journal of Clinical Hepatology |
| PublicationYear | 2020 |
| Publisher | Journal of Clinical Hepatology 苏州大学附属第一医院介入科,江苏苏州215000 |
| Publisher_xml | – name: Journal of Clinical Hepatology – name: 苏州大学附属第一医院介入科,江苏苏州215000 |
| SSID | ssib051369456 ssib061082477 ssj0041983 ssib001103858 ssib053243598 ssib002264326 ssib038074677 |
| Score | 2.2205236 |
| Snippet | 摘要:目的评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略。方法选取2008年1月-2017年12月在苏州大学附属第一医院行TACE治疗的肝细胞癌患者。为研究不同ABCR分值患者再次TACE治疗的有效性,选取连续行TACE治疗 (至少2次,且不联合全身系统治疗)... R735.7; 目的 评估ABCR评分系统对肝细胞癌患者再次TACE治疗的指导价值,并探讨ABCR评分为1～3分患者的治疗策略.方法... |
| SourceID | wanfang proquest |
| SourceType | Aggregation Database |
| StartPage | 1980 |
| SubjectTerms | Chemoembolization Liver cancer Medical prognosis |
| Title | ABCR评分系统对经肝动脉化疗栓塞术治疗肝细胞癌预后的评估价值 |
| URI | https://www.proquest.com/docview/3240139300 https://d.wanfangdata.com.cn/periodical/lcgdbzz202009014 |
| Volume | 36 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LaxRBEC6SLIZcxCdG4xIh1zE9M90z3QeR3ZglCFkkuLC30DPdkyCyiTEi7El0CSpBBSGiaHycvK3oQWTyczI767-weh7uevHYU0MzFNXVX01VfQWwEDgqckKfWH4USYvywLaExigFjUdpwZjkzPQOrza9lRa92WbtCWiWvTCmrLL0iZmjVluh-Ue-aIjjEK24hFzfvmeZqVEmu1qO0JDFaAV1LaMYm4QKumSOdl-pLzdvrY0Agk3-YW8xbaRjAMawr9Mxgjdmu56gI7YZhl9hKO_KNWIP7mSdnLnvpxjC5yX9GKQzRBPTsGDiYuGJxTvZqb76V4SxqUMyjlXTQTQGb088lJ1IdjbG7rnGKThZANT5Wm5Rp2Giu3kGpleLFPxZaNXqS2vDfi95upf-iNP4Y9L_lcYvh48_JM-_DnvPkv2D9ODN4NPr5PPh4H1_8D3GJUrTeG_45DB9u__7Sy959SJ918NNjo--Hcc_k0dH56DVWL69tGIVsxmsbdu1qcVQ45KEXHgIKbQXRJqKAEMhRylOhHaVI6jKG1m1x32BKEsjkOcB0R4-YO55mOpsdfQFmA8DTqTSLl6Tmtq-LUlkis0IdSUNtevMwlypnPXigN1fH5nDLFwpFDaS3g03VNDtGg0Tkye--P8tLsGMeTUvHZuDqd2dB_oyYo3doAqTftuvQqVWv1FvVAtz-gPMR-O7 |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NaxQxFA9li7UX8ROrVVeox7FJJjObHIq0tWVru4uULvS2ZiaZipRttZXinkSXolJUECqK1o-TtxU9iEzxr-nsrP-FL_PhrhdvPWZCApO8yfu9efn9HkJjHlUB9UvYKgWBtBj3iCU0RClgPEoLx5HcMdzhStUt19iNZWd5AP3KuTDmWmV-JiYHtVrzzT_ycSMcB2jFxvja-l3LVI0y2dW8hIbMSiuoiURiLCN2zOsHWxDCbUzMXYf9vkLp7MzSdNnKqgxY68QmzHJgrMQ-Fy44R-16gWbCA1BPleJYaFtRwVRKydQuLwnACxogKfewduGBqRoBLmCQGYZrAQ1OzVRvLvYACcH_qMUY2mofYDJq76xPUM4htitYT93Ggbc2Ent5G7AOpwlzNPU1jAieUggwgZDScYfQmInDhSvG7ySnyNW_XRALU5xouhrGUh-cPrIlG4FsrPT51dnj6FgGiIuTqQWfQAPN2yfRUCVL-Z9Ctcmp6cVuuxU92Y6_h3H4IWr_jMMX3Ufvo2dfuq2n0c5uvPu68_FV9Gmv867d-RZCE3rjcLv7eC9-s_P7cyt6-Tx-24JJDva_HoQ_oof7p1HtUHbpDCo01hr6LCr6HsdSaRvcsmakRCQOzOU2zGzJfG3TETSaL049-6A36j3zG0GXswXr9a76K8prNs0KY5OXPvf_KS6ho-WlykJ9Ya46fx4Nm2HptbVRVNi8d19fAJyz6V3MjKmIbh22_f4BR-cckg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=ABCR%E8%AF%84%E5%88%86%E7%B3%BB%E7%BB%9F%E5%AF%B9%E7%BB%8F%E8%82%9D%E5%8A%A8%E8%84%89%E5%8C%96%E7%96%97%E6%A0%93%E5%A1%9E%E6%9C%AF%E6%B2%BB%E7%96%97%E8%82%9D%E7%BB%86%E8%83%9E%E7%99%8C%E9%A2%84%E5%90%8E%E7%9A%84%E8%AF%84%E4%BC%B0%E4%BB%B7%E5%80%BC&rft.jtitle=%E4%B8%B4%E5%BA%8A%E8%82%9D%E8%83%86%E7%97%85%E6%9D%82%E5%BF%97&rft.au=%E6%9D%A8%E4%BF%8A&rft.au=%E5%8D%B0%E4%BA%8E&rft.au=%E5%80%AA%E6%89%8D%E6%96%B9&rft.au=%E6%9C%B1%E6%99%93%E9%BB%8E&rft.date=2020-09-01&rft.pub=%E8%8B%8F%E5%B7%9E%E5%A4%A7%E5%AD%A6%E9%99%84%E5%B1%9E%E7%AC%AC%E4%B8%80%E5%8C%BB%E9%99%A2%E4%BB%8B%E5%85%A5%E7%A7%91%2C%E6%B1%9F%E8%8B%8F%E8%8B%8F%E5%B7%9E215000&rft.issn=1001-5256&rft.volume=36&rft.issue=9&rft.spage=1980&rft.epage=1984&rft_id=info:doi/10.3969%2Fj.issn.1001-5256.2020.09.014&rft.externalDocID=lcgdbzz202009014 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Flcgdbzz%2Flcgdbzz.jpg |